NCT00701688View on ClinicalTrials.gov

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

February 29, 2012

Conditions
Oral MucositisHematopoietic Stem Cell Transplantation
Interventions
DRUG

Palifermin

Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00701688 - Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter